First filing for GSK and HGS's Benlysta for lupus
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Human Genome Sciences' candidate for systemic lupus erythematosus (SLE), Benlysta (belimumab), has been filed in the EU, its first market. If approved, it could become the first new drug for the condition in 50 years.